Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model1

Sayers, 1998, Long-term results of femorotibial bypass with vein or polytetrafluoroethylene, Br. J. Surg, 85, 934, 10.1046/j.1365-2168.1998.00765.x Biancari, 2001, Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia, Eur. J. Vasc. Endovasc. Surg, 21, 137, 10.1053/ejvs.2000.1290 Clowes, 1983, Mechanisms of stenosis after arterial injury, Lab. Invest, 49, 208 Guyton, 1980, Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin, Circ. Res, 46, 625, 10.1161/01.RES.46.5.625 Clowes, 1977, Suppression by heparin of smooth muscle cell proliferation in injured arteries, Nature, 265, 625, 10.1038/265625a0 Letourneur, 1995, Heparin binding, internalization, and metabolism in vascular smooth muscle cells: I. Upregulation of heparin binding correlates with antiproliferative activity, J. Cell. Physiol, 165, 676, 10.1002/jcp.1041650327 Clowes, 1992, Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery, Circ. Res, 70, 1128, 10.1161/01.RES.70.6.1128 Chen, 2000, Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons, J. Vasc. Surg, 31, 354, 10.1016/S0741-5214(00)90165-4 Lin, 2003, Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model, J. Surg. Res, 112, 84, 10.1016/S0022-4804(03)00124-0 Lin, 2003, Heparin-coated balloon-expandable stent reduces intimal hyperplasia in the iliac artery in baboons, J. Vasc. Interv. Radiol, 14, 603, 10.1097/01.RVI.0000071088.76348.23 Sanchez, 1995, Control of contact activation on end-point immobilized heparin, J. Biomed. Mater. Res, 29, 655, 10.1002/jbm.820290513 Riesenfeld, 1995, Surface modification with functionally active heparin, Med. Device Technol, 6, 24 Chen, 1996, Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft, Circulation, 94, 1989, 10.1161/01.CIR.94.8.1989 Daugherty, 1978, Improved treatment of popliteal arterial injuries using anticoagulation and extra-anatomic reconstruction, Arch. Surg, 113, 1317, 10.1001/archsurg.1978.01370230107013 Whiffen, 1964, Heparin application to graphite-coated intravascular prostheses, Surgery, 56, 404 Ferguson, 1998, Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition, Am. Heart J, 135, S35, 10.1016/S0002-8703(98)70296-0 Rohrer, 1992, High-dose heparin suppresses platelet alpha granule secretion, J. Vasc. Surg, 15, 1000, 10.1016/0741-5214(92)90456-I Xia, 2002, Heparin induces differentiation of CD1a+ dendritic cells from monocytes, J. Immunol, 168, 1131, 10.4049/jimmunol.168.3.1131 Tayama, 2000, Biocompatibility of heparin-coated extracorporeal bypass circuits, Artif. Organs, 24, 618, 10.1046/j.1525-1594.2000.06615.x Dewanjee, 1994, Neutrophil dynamics and retention in lung, oxygenator, and arterial filter during cardiopulmonary bypass in a pig model, ASAIO J, 40, M547, 10.1097/00002480-199407000-00059 Serruys, 1996, Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study, Circulation, 93, 412, 10.1161/01.CIR.93.3.412 Fager, 1992, Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin, In Vitro Cell Dev. Biol, 28A, 168, 10.1007/BF02631087 Au, 1993, Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration, Haemostasis, 23, 177 Reilly, 1989, Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle, J. Biol. Chem, 264, 6990, 10.1016/S0021-9258(18)83529-3 Castellot, 1985, Binding and internalization of heparin by vascular smooth muscle cells, J. Cell. Physiol, 124, 13, 10.1002/jcp.1041240104 Ottlinger, 1993, Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells, J. Biol. Chem, 268, 19173, 10.1016/S0021-9258(19)36492-0 Herbert, 1996, Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo, J. Biol. Chem, 271, 25928, 10.1074/jbc.271.42.25928 Au, 1994, Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B, Circ. Res, 75, 15, 10.1161/01.RES.75.1.15 Nugent, 1993, Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells, Circ. Res, 73, 1051, 10.1161/01.RES.73.6.1051 Reilly, 1987, Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor, J. Cell. Physiol, 131, 149, 10.1002/jcp.1041310203 McCaffrey, 1989, Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex, J. Cell. Biol, 109, 441, 10.1083/jcb.109.1.441 Au, 1992, Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells, Circ. Res, 70, 1062, 10.1161/01.RES.70.5.1062 Faxon, 1994, Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial, Circulation, 90, 908, 10.1161/01.CIR.90.2.908 Laskey, 1990, Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus, Am. J. Cardiol, 65, 179, 10.1016/0002-9149(90)90081-B Au, 1992, Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis, J. Biol. Chem, 267, 3438, 10.1016/S0021-9258(19)50750-5 Devine, 2001, Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting, J. Vasc. Surg, 33, 533, 10.1067/mva.2001.113578